Related Experiment Video
Updated: May 12, 2026
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
iNOS: a potential therapeutic target for malignant glioma
1Department of Anatomy and Neurobiology, Washington University School of Medicine, Campus Box 8108, 660 South Euclid Ave, St Louis, MO 63110, USA.
Abstract:
Glioblastoma is the most aggressive adult primary brain tumor. Although progress has been made in understanding the molecular mechanisms underlying these tumors, current treatments are ineffective. Recent studies have identified iNOS as a critical regulator of glial transformation downstream of EGFRvIII/STAT3 signaling, a key oncogenic pathway in glioblastoma. STAT3 directly binds the promoter of the iNOS gene and thereby stimulates its expression. Importantly, inhibition of iNOS by genetic and pharmacological approaches impedes glial cell proliferation, invasiveness, and tumor growth in vivo. iNOS expression is also elevated in a population of human brain tumor stem cells (BTSCs), and iNOS is required for BTSC proliferation and tumorigenesis. Together, these findings suggest that development of iNOS-targeted therapies may prove valuable in the treatment of glioblastoma. Here, we review our current understanding of iNOS signaling in the regulation of glioblastoma pathogenesis and the potential mechanisms by which iNOS inhibition might suppress the malignant behavior of these devastating tumors.
Insights
Targeting inducible nitric oxide synthase (iNOS) may offer a new glioblastoma treatment. Inhibiting iNOS impedes tumor growth and proliferation in brain tumor stem cells.
Area of Science:
- Oncology
- Molecular Biology
- Neuroscience
Background:
- Glioblastoma is an aggressive brain tumor with limited treatment options.
- Epidermal growth factor receptor variant III (EGFRvIII) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling are key oncogenic pathways.
- Inducible nitric oxide synthase (iNOS) has emerged as a critical regulator in glioblastoma.
Purpose of the Study:
- To review the role of iNOS signaling in glioblastoma pathogenesis.
- To explore the potential of iNOS-targeted therapies for glioblastoma treatment.
Main Methods:
- Review of recent studies on iNOS signaling in glioblastoma.
- Analysis of STAT3's direct binding and regulation of iNOS gene expression.
- Examination of in vivo and brain tumor stem cell (BTSC) models.
Main Results:
- STAT3 directly upregulates iNOS expression, promoting glial transformation.
- Inhibition of iNOS (genetically or pharmacologically) reduces glioblastoma cell proliferation, invasiveness, and tumor growth.
- Elevated iNOS expression is observed in human BTSCs, crucial for their proliferation and tumorigenesis.
Conclusions:
- iNOS is a critical mediator of glioblastoma pathogenesis.
- Targeting iNOS presents a promising therapeutic strategy for glioblastoma, including brain tumor stem cells.
